GSK will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs.The British pharma giant said Wednesday that it will pay the ...

British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in ...

45. LONDON — GSK said Wednesday it would purchase an experimental liver disease medicine from Boston Pharmaceuticals for $1.2 billion upfront, seeking to build up its pipeline of future medicines.

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

The agreement announced Wednesday brings GSK efimosfermin alfa, a Boston Pharmaceuticals drug that is ready for Phase 3 testing. In addition to metabolic dysfunction-associated steatohepatitis ...

GSK GSK0.87%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

The new drug, licensed years ago by Novartis AG to closely held Boston Pharmaceuticals, should have benefits beyond any GLP-1 therapy patients are taking, GSK said. GSK shares rose less than 1% in ...